RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine.
The vaccine development will be based on Chimeron Bio’s ChaESAR self-amplifying RNA technology and will integrate Mason’s complimenting expertise and Biomedical Research Laboratory (BRL), a National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) supported, state-of-the-art Regional Biocontainment Laboratory for the rapid screening of the company’s vaccine pipeline.
ChaESAR, a self-amplifying RNA delivery technology, can deliver highly immunogenic viral genes to elicit rapid and sustained immune response.
ChaESAR’s ability to amplify the production of viral antigens inside the body is expected to generate a vaccine response at much lower doses compared to traditional mRNA approaches.
Moreover, the ChaESARTM particle is a self-assembling delivery system which bypasses the need for expensive in-vitro RNA synthesis. Due to its superior science and manufacturing advantage, a single batch of a low-dose ChaESARTM formulation could vaccinate many more people worldwide, thereby offering a rapid, effective, and affordable solution.